Takeda Pharmaceutical Company Limited American Depositary Share

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

TAK

Financials

Takeda Pharmaceutical Company Limited American Depositary Share

Haberler

ADMA Crashes 42.5% YTD: Right Time to Buy the Stock?

Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

My Top 4 Pharma Picks Under Rising Geopolitical Risk

Spyre Therapeutics Flies On Takeda-Rivaling Ulcerative Colitis Results

Is ADMA Poised for Margin Growth and Supply Expansion in 2026?

Will Lead Drug Asceniv Fuel ADMA's Top-Line Growth in 2026?

Eli Lilly To Buy Centessa Pharma For Up To $7.8 Billion; Centessa Shares Skyrocket

Raymond James, Alumis hissesi için Güçlü Al tavsiyesini korudu

Kamada: From Buy To Hold After 22.4% Surge (Rating Downgrade) (NASDAQ:KMDA)

Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy Transcript

Takeda Pharmaceutical Company Limited (TAK) Discusses Zasocitinib Phase III Psoriasis Data and Commercial Strategy - Slideshow (NYSE:TAK) 2026-03-28

Denali Wins FDA Nod for Hunter Syndrome Drug, Stock Up